{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T14:37:34Z","timestamp":1790087854010,"version":"4.0.1"},"reference-count":23,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T00:00:00Z","timestamp":1770076800000},"content-version":"vor","delay-in-days":1313,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2022,5,7]],"date-time":"2022-05-07T00:00:00Z","timestamp":1651881600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Zoetis Japan,Inc."}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,7,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The recommended doxorubicin (DOX) dose for small dogs is 1\u00a0mg\/kg. Recent data suggest that DOX-induced gastrointestinal (GI) toxicosis can be reduced with maropitant treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To investigate the incidence of adverse events (AEs) in small-breed dogs administered a single 25\u2009mg\/m2 DOX followed by administration of maropitant (DOX25). The primary aim was to assess myelo- and GI toxicoses for 2\u2009weeks after DOX administration. The secondary aim was to compare the incidence and grades of AEs found in the DOX25 group with a historical control group (DOX 1\u00a0mg\/kg without administration of antiemetic or antidiarrheal medications).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Animals<\/jats:title>\n                    <jats:p>Nineteen small-breed tumor-bearing dogs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A prospective, observational study of tumor-bearing dogs, weighing 5 to 10\u00a0kg, administered a single 25\u2009mg\/m2 dose of DOX IV, followed by administration of maropitant for the next 5\u2009days.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Inappetence, vomiting, and diarrhea were found in 7\/19, 2\/19, and 6\/19 of the DOX25 dogs, respectively. Neutropenia and thrombocytopenia was 12\/19 and 3\/19, respectively. Most AEs were grades 1 and 2, except for grades 3 and 4 inappetence and neutropenia in 3 and 4 dogs, respectively. Furthermore, febrile neutropenia occurred in 3\/19 dogs in the DOX25 group. All AEs between the DOX25 and historical control groups were not significantly different.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions and Clinical Importance<\/jats:title>\n                    <jats:p>Vomiting and diarrhea were deemed acceptable with 25\u2009mg\/m2 DOX followed by maropitant treatment in 5 to 10\u00a0kg dogs; however, additional supportive care might be needed for dogs with inappetence and neutropenia.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/jvim.16439","type":"journal-article","created":{"date-parts":[[2022,5,7]],"date-time":"2022-05-07T06:55:15Z","timestamp":1651906515000},"page":"1409-1415","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Evaluation of adverse events in small-breed dogs treated with maropitant and a single dose of doxorubicin"],"prefix":"10.1093","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1021-7735","authenticated-orcid":false,"given":"Fukiko","family":"Matsuyama","sequence":"first","affiliation":[{"name":"Japan Small Animal Cancer Center, Japan Small Animal Medical Center , Tokorozawa-shi, Saitama,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kei","family":"Harada","sequence":"additional","affiliation":[{"name":"Japan Small Animal Cancer Center, Japan Small Animal Medical Center , Tokorozawa-shi, Saitama,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eri","family":"Fukazawa","sequence":"additional","affiliation":[{"name":"Japan Small Animal Cancer Center, Japan Small Animal Medical Center , Tokorozawa-shi, Saitama,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0925-0981","authenticated-orcid":false,"given":"Masanao","family":"Ichimata","sequence":"additional","affiliation":[{"name":"Japan Small Animal Cancer Center, Japan Small Animal Medical Center , Tokorozawa-shi, Saitama,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuko","family":"Nakano","sequence":"additional","affiliation":[{"name":"Veterinary Cancer Center, Hayashiya Animal Hospital , Kyoto,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0100-8579","authenticated-orcid":false,"given":"Tetsuya","family":"Kobayashi","sequence":"additional","affiliation":[{"name":"Japan Small Animal Cancer Center, Japan Small Animal Medical Center , Tokorozawa-shi, Saitama,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,7,1]]},"reference":[{"key":"2026020304002048700_jvim16439-bib-0001","first-page":"221","article-title":"Single agent therapy with adriamycin for canine lymphoma","volume":"25","author":"Postorino","year":"1989","journal-title":"J Am Anim Hosp Assoc"},{"key":"2026020304002048700_jvim16439-bib-0002","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1111\/j.1939-1676.2001.tb01243.x","article-title":"Single agent chemotherapy with doxorubicin for feline lymphoma: a retrospective study of 19 cases (1994-1997)","volume":"15","author":"Kristal","year":"2001","journal-title":"J Vet Intern Med"},{"key":"2026020304002048700_jvim16439-bib-0003","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.2460\/javma.2002.220.1813","article-title":"Evaluation of treatment with doxorubicin and piroxicam or doxorubicin alone for multicentric lymphoma in dogs","volume":"220","author":"Mutsaers","year":"2002","journal-title":"J Am Vet Med Assoc"},{"key":"2026020304002048700_jvim16439-bib-0004","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.2460\/javma.237.9.1052","article-title":"Response rate after administration of a single dose of doxorubicin in dogs with B-cell or T-cell lymphoma: 41 cases (2006-2008)","volume":"237","author":"Beaver","year":"2010","journal-title":"J Am Vet Med Assoc"},{"key":"2026020304002048700_jvim16439-bib-0005","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.1939-1676.1993.tb01021.x","article-title":"Evaluation of prognostic factors and sequential combination chemotherapy with doxorubicin for canine lymphoma","volume":"7","author":"Keller","year":"1993","journal-title":"J Vet Intern Med"},{"key":"2026020304002048700_jvim16439-bib-0006","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1111\/j.1939-1676.1996.tb02085.x","article-title":"Surgery and doxorubicin in dogs with hemangiosarcoma","volume":"10","author":"Ogilvie","year":"1996","journal-title":"J Vet Intern Med"},{"key":"2026020304002048700_jvim16439-bib-0007","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.2460\/javma.1995.206.10.1555","article-title":"Results of surgery and doxorubicin chemotherapy in dogs with osteosarcoma","volume":"206","author":"Berg","year":"1995","journal-title":"J Am Vet Med Assoc"},{"key":"2026020304002048700_jvim16439-bib-0008","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.2460\/javma.1989.195.11.1584","article-title":"Acute and short-term toxicoses associated with the administration of doxorubicin to dogs with malignant tumors","volume":"195","author":"Ogilvie","year":"1989","journal-title":"J Am Vet Med Assoc"},{"key":"2026020304002048700_jvim16439-bib-0009","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1111\/j.1939-1676.2010.0611.x","article-title":"Efficacy of maropitant in the prevention of delayed vomiting associated with administration of doxorubicin to dogs","volume":"24","author":"Rau","year":"2010","journal-title":"J Vet Intern Med"},{"key":"2026020304002048700_jvim16439-bib-0010","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1292\/jvms.10-0176","article-title":"Gastrointestinal and hematologic adverse events after administration of vincristine, cyclophosphamide, and doxorubicin in dogs lymphoma that underwent a combination multidrug chemotherapy protocol","volume":"72","author":"Tomiyasu","year":"2010","journal-title":"J Vet Med Sci"},{"key":"2026020304002048700_jvim16439-bib-0011","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1111\/j.1476-5829.2006.00123.x","article-title":"Efficacy of injectable maropitant (Cerenia) in a randomized clinical trial for prevention and treatment of cisplatin-induced emesis in dogs presented as veterinary patients","volume":"5","author":"Vail","year":"2007","journal-title":"Vet Comp Oncol"},{"key":"2026020304002048700_jvim16439-bib-0012","doi-asserted-by":"crossref","first-page":"48","DOI":"10.2460\/ajvr.68.1.48","article-title":"Efficacy of maropitant for treatment and prevention of emesis caused by intravenous infusion of cisplatin in dogs","volume":"68","author":"de la Puente-Redondo","year":"2007","journal-title":"Am J Vet Res"},{"key":"2026020304002048700_jvim16439-bib-0013","first-page":"157","article-title":"Withrow and ManEwen's Small Animal Clinical Oncology","author":"Gustafson","year":"2012","edition":"5th ed."},{"key":"2026020304002048700_jvim16439-bib-0014","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.2460\/ajvr.1994.55.11.1587","article-title":"Comparison of body surface area-based and weight-based dosage protocols for doxorubicin administration in dogs","volume":"55","author":"Arrington","year":"1994","journal-title":"Am J Vet Res"},{"key":"2026020304002048700_jvim16439-bib-0015","doi-asserted-by":"crossref","first-page":"650","DOI":"10.2460\/javma.236.6.650","article-title":"Case-control study to evaluate risk factors for the development of sepsis (neutropenia and fever) in dogs receiving chemotherapy","volume":"236","author":"Sorenmo","year":"2010","journal-title":"J Am Vet Med Assoc"},{"key":"2026020304002048700_jvim16439-bib-0016","first-page":"417","article-title":"Veterinary cooperative oncology group - common terminology criteria for adverse events (VCOG-CTCAE) following chemotherapy or biological antineoplastic therapy in dogs and cats v1.1","volume":"14","year":"2011","journal-title":"Vet Comp Oncol"},{"key":"2026020304002048700_jvim16439-bib-0017","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/S1471-4892(01)00100-X","article-title":"Tachykinin receptors in the gut: physiological and pathological implications","volume":"1","author":"Holzer","year":"2001","journal-title":"Curr Opin Pharmacol"},{"key":"2026020304002048700_jvim16439-bib-0018","doi-asserted-by":"crossref","first-page":"3440","DOI":"10.1007\/s10620-013-2709-7","article-title":"Increased expression of 5-HT3 and NK1 receptors in 5-flurouracil-induced mucositis in mouse jejunum","volume":"58","author":"Matsumoto","year":"2013","journal-title":"Dig Dis Sci"},{"key":"2026020304002048700_jvim16439-bib-0019","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1136\/gut.47.3.387","article-title":"Neurokinin-1 receptor expression in inflammatory bowel disease: molecular quantitation and localisation","volume":"47","author":"Goode","year":"2000","journal-title":"Gut"},{"key":"2026020304002048700_jvim16439-bib-0020","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1002\/ibd.21422","article-title":"Role of sensory neurons in colitis: increasing evidence for a neuroimmune link in the gut","volume":"17","author":"Engel","year":"2011","journal-title":"Inflamm Bowel Dis"},{"key":"2026020304002048700_jvim16439-bib-0021","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1186\/s12917-017-1156-7","article-title":"Anti-nausea effects and pharmacokinetics of ondansetron, maropitant and metoclopramide in a low-dose cisplatin model of nausea and vomiting in the dog: a blinded crossover study","volume":"13","author":"Kenward","year":"2017","journal-title":"BMC Vet Res"},{"key":"2026020304002048700_jvim16439-bib-0022","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1111\/jvim.14607","article-title":"A prospective, randomized, masked, placebo-controlled clinical study of capromoreline in dogs with reduced appetite","volume":"30","author":"Zollers","year":"2016","journal-title":"J Vet Intern Med"},{"key":"2026020304002048700_jvim16439-bib-0023","article-title":"Plumb's Veterinary Drug Handbook","author":"Plumb","year":"2018","edition":"9th ed."}],"container-title":["Journal of Veterinary Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jvim.16439","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/jvim.16439","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/jvim\/article-pdf\/36\/4\/1409\/66665391\/jvim16439.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jvim\/article-pdf\/36\/4\/1409\/66665391\/jvim16439.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T09:00:31Z","timestamp":1770109231000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jvim\/article\/36\/4\/1409\/8448941"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,1]]},"references-count":23,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,7,1]]}},"URL":"https:\/\/doi.org\/10.1111\/jvim.16439","relation":{},"ISSN":["1939-1676"],"issn-type":[{"value":"1939-1676","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,7]]},"published":{"date-parts":[[2022,7,1]]},"assertion":[{"value":"2021-09-09","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-04-27","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-05-07","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}